BRAF and melanoma: Our initial studies addressed the hypothesis that the triple BRAF/MEK/CDK4/6 combination in BRAF mutant melanoma cells would potentiate the metabolic effects of MAPK pathway inhibition and lead to enhanced suppression of glycolysis and/or increased OXPHOS and reactive oxygen species (ROS) production in melanoma cells.